Top Recruiting Trials
20 actively recruiting studies
Exercise in Child Health
University of California, Irvine
n=240
University of California, Irvine
Irvine, California
Intervention OTHER: Exercise — Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the ne...
Eligibility Ages 10 Years – 17 Years
Natural History of Bronchiectasis
National Heart, Lung, and Blood Institute (NHLBI)
n=900
National Institutes of Health Clinical Center
Bethesda, Maryland
Eligibility Ages 5 Years – 100 Years
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Insel Gruppe AG, University Hospital Bern
n=500
University Children's Hospital Bern
Bern
Intervention OTHER: no intervention
Eligibility Ages 0 Years – 18 Years
Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis
Qianfoshan Hospital
n=134
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong
Intervention DRUG: Staphylococcus and Neisseria Tablets — 0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was...
Eligibility Ages 18 Years
Regional Phenotyping of CF and Non-CF Bronchiectasis
Children's Hospital Medical Center, Cincinnati
n=100
Penny New
Cincinnati, Ohio
Intervention DRUG: Xenon — Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natu...
Eligibility Ages 5 Years – 100 Years
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
Rhode Island Hospital
n=15
Boston Children's Hospital
Boston, Massachusetts
Intervention BEHAVIORAL: Low Glycemic Load Diet — Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence ...
Eligibility Ages 18 Years – 70 Years
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Dana-Farber Cancer Institute
n=500
Brigham and Women's Hospital
Boston, Massachusetts
Intervention GENETIC: Data and Specimen Collection — * Provide blood and/or saliva sample
* Answer short questionnaires
* Consider consenting to other optional parts of the ...
Eligibility Ages 18 Years
Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes
West Kazakhstan Marat Ospanov Medical University
n=310
Outpatient clinics of Aktobe region, West Kazakhstan Marat Ospanov Medical University
Aktobe, Aktobe
Eligibility Ages 18 Years – 74 Years
Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial
University Hospital, Tours
n=100
Cystic Fibrosis Resource and Competence Centre, University Hospital, Angers
Angers
Intervention OTHER: DIAPASOM program — A program of adapted physical activity carried out remotely by a specialist instructor, combined with personalized diete...
Eligibility Ages 18 Years
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
University of California, Los Angeles
n=170
University of California, Los Angeles
Los Angeles, California
Eligibility Ages 18 Years – 99 Years
A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
Haisco Pharmaceutical Group Co., Ltd.
n=669
Yixing People's Hospital, Yixing, Jiangxi Recruiting
Yixingcun, Jiangxi
Intervention DRUG: HSK31858, tablet — HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52...
Eligibility Ages 18 Years
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Eli Lilly and Company
n=510
AllerVie Clinical Research
Birmingham, Alabama
Intervention DRUG: LY3650150 — Administered SC.
Eligibility Ages 12 Years
CRS Questionnaire Validation Project
The European Forum for Research and Education in Allergy and Airway Diseases
n=1000
UCLA Santa Monica Medical Center
Santa Monica, California
Eligibility Ages 18 Years
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
Chiesi Farmaceutici S.p.A.
n=45
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection
Cambridge
Intervention DRUG: CHF6333 — CHF6333 Part I SAD; CHF6333 Part II MD.
Eligibility Ages 18 Years – 80 Years
Epididymis Protein 4 and Pulmonary Function With Quality Improvement Protocol Among Cystic Fibrosis Patients
Ain Shams University
n=35
Ain Shams university
Cairo, Abbasia
Eligibility Ages 6 Years
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
CHU de Reims
n=75
Chu Reims
Reims
Intervention BIOLOGICAL: Blood sampling & Chest CT without injection — Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leu...
Eligibility Ages 18 Years
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Peking University People's Hospital
n=3000
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality
CF Wellness Program
Johns Hopkins University
n=80
National Jewish Health
Denver, Colorado
Intervention BEHAVIORAL: CF Wellness Program — Intervention modules are 1) Introduction \& Fatigue Explained, 2) Finding Balance between Activity \& Rest, 3) Physical ...
Eligibility Ages 18 Years
Cardiopulmonary Responses to 6-Minute Stepper Test in Bronchiectasis Versus Healthy Controls
Hacettepe University
n=60
Hacettepe University Faculty of Physical Therapy and Rehabilitation
Ankara
Intervention OTHER: No intervention; Observational study — No intervention
Eligibility Ages 18 Years
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
National Institute of Allergy and Infectious Diseases (NIAID)
n=10000
National Institutes of Health Clinical Center
Bethesda, Maryland
Eligibility Ages 3 Years – 100 Years